When Moderna (Nasdaq: MRNA) presents its 2022 financial results later this month, sales of its COVID-19 vaccine Spikevax are expected to be around $19.5 billion, a figure the young biotech company could only have dreamt about a few years ago.
This makes it the second highest selling COVID-19 vaccine, behind only Pfizer’s (NYSE: PFE), which had 2022 sales of $37.8 billion.
"Spikevax could struggle to compete with direct competitors Comirnaty and new entrants such as COVID-19 therapeutics"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze